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Abstract 
SPI1 (also known as PU.1) is a dominant but transient regulator in early T-cell precursors and a 
potent transcriptional controller of developmentally important pro-T cell genes. Before T-lineage 
commitment, open chromatin is frequently occupied by PU.1, and many PU.1 sites lose 
accessibility when PU.1 is later downregulated. Pioneering activity of PU.1 was tested in this 
developmentally dynamic context, by quantitating the relationships between PU.1 occupancy 
and site quality and accessibility as PU.1 levels naturally declined in pro-T cell development, 
and by using stage-specific gain and loss of function perturbations to relate binding to effects on 
target genes. PU.1 could bind closed genomic sites, but rapidly opened many of them, despite 
the absence of its frequent collaborator, CEBPA. RUNX motifs and RUNX1 binding were often 
linked to PU.1 at open sites, but highly expressed PU.1 could bind its sites without RUNX1. The 
dynamic properties of PU.1 engagements implied that PU.1 binding affinity and concentration 
determine its occupancy choices, but with quantitative tradeoffs for occupancy between site 
sequence quality and stage-dependent site accessibility in chromatin. At non-promoter sites 
PU.1 binding criteria were more stringent than at promoters, and PU.1 was also much more 
effective as a transcriptional regulator at non-promoter sites where local chromatin accessibility 
depended on the presence of PU.1. Notably, closed chromatin presented a qualitative barrier to 
occupancy by the PU.1 DNA binding domain alone. Thus, effective pioneering at closed 
chromatin sites also depends on requirements beyond site recognition served by non-DNA 
binding domains of PU.1.  
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Introduction 
In development, a cell’s regulatory history determines different pre-existing chromatin 
accessibility landscapes, which in turn may bias a transcription factor (TF) to engage different 
sites in different contexts (Treiber et al. 2010). However, questions remain about how much of a 
barrier chromatin state may pose, or whether there is a clear distinction between transcription 
factors that are highly chromatin-limited and other, “pioneer” factors, that might engage their 
sites impervious to chromatin state. SPI1 (also known as PU.1, used throughout this article) 
works both to mediate developmental choices of blood progenitor cells and to serve the 
alternative developmental fates – associated with different epigenetic landscapes – that emerge 
from these choices. Its role in T-cell development is confined to the early stages leading up to T-
cell lineage commitment, where it occupies tens of thousands of genomic sites in uncommitted 
cells but disappears in a programmed way during commitment. This dynamic transition offers a 
rare window into the quantitative contributions of affinity, chromatin context, factor 
concentration, and developmental history as predictors of PU.1 function.  
 
The best studied roles for PU.1 involve its sustained actions as a lineage-determining 
transcription factor in myeloid, dendritic-cell, and B cell development, where it can open closed 
chromatin and recruit other transcription factors including CEBPA, NF-κB complexes, and IRF4 
or 8 (Escalante et al. 2002; Carotta et al. 2010; Heinz et al. 2010; Natoli et al. 2011; Ostuni et al. 
2013; McAndrew et al. 2016)[reviewed in (Gosselin and Glass 2014)]. In the macrophage 
context, PU.1 can act as a pioneer factor, capable of evicting nucleosomes (Barozzi et al. 
2014), but collaboration with known partners also affects PU.1 site choices (Heinz et al. 2013). 
PU.1 is also crucial for multiple other hematopoietic lineages (Back et al. 2005; Iwasaki et al. 
2005; Nutt et al. 2005) including the earliest stages of T-cell development (Champhekar et al. 
2015). Although most mature T cells express no PU.1, early-stage pro-T cells maintain 
substantial PU.1 through multiple cell divisions before downregulating it during T-cell lineage 
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commitment (Yui et al. 2010; Zhang et al. 2012). CEBP or IRF family factors that PU.1 
cooperates with in myeloid and B cells are expressed little if at all in early T-lineage cells, which 
should affect PU.1 genome-wide binding profiles (Heinz et al. 2013). Yet its potential for 
pioneering activity in other cell types, enhanced by its unusual protein stability (Kueh et al. 
2013), could make it a strong contributor to “epigenetic memory” in early pro-T cells. Here we 
have investigated how PU.1 sets and responds to the chromatin context in which the T-cell 
program emerges. 
 
PU.1 expression is well established in multilineage lymphoid precursors before they enter the 
thymus. Within the thymus, pro-T cells proliferate and differentiate through stages called DN1, 
DN2a, DN2b, and DN3a before they express T-cell receptor proteins. They become committed 
to the T-cell fate only during the DN2a to DN2b transition (Fig. 1A), which follows multiple cell 
divisions under the influence of thymic Notch pathway signaling [rev. in (Yui and Rothenberg 
2014)]. Commitment encompasses a global shift in 3-D chromatin associations (Hu et al. 2018) 
and in regulatory gene expression (Rothenberg et al. 2016), and this is when PU.1 expression is 
finally shut down. Until commitment, PU.1 binds to >30,000 sites in DN1 and DN2a pro-T cells, 
distinct from sites occupied in B and myeloid lineage cells (Zhang et al. 2012). It supports 
proliferation and restrains specific alternative lineage genes, but slows progression toward 
commitment, thus enforcing correct timing of access to T-lineage genes (Champhekar et al. 
2015). Previously, we identified impacts of PU.1 on specific, developmentally relevant genes by 
acute gain and loss of function perturbations (Anderson et al. 2002; Dionne et al. 2005; Franco 
et al. 2006; Del Real and Rothenberg 2013; Champhekar et al. 2015). PU.1 repressed as well 
as activated genes (Dionne et al. 2005; Franco et al. 2006; Del Real and Rothenberg 2013), 
antagonizing Notch signaling in early T-cell development and delaying activation of many T-cell 
genes until commitment. However, PU.1 binding sites globally appeared to be associated with 
active chromatin and actively expressed genes (Zhang et al. 2012), leaving the repression 
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unexplained. Furthermore, most genes linked to PU.1 occupancy in vivo do not change 
expression as PU.1 levels decrease in T-cell development (Zhang et al. 2012), implying that 
most PU.1 binding events do not control transcription. Here, therefore, we have used gain and 
loss of function perturbations coupled with genome-wide analyses of the changes they induce in 
binding, chromatin state, and transcription of developmentally significant genes to show how 
PU.1 selects the sites that it will occupy in changing chromatin contexts, respecting or reshaping 
local chromatin states, and how its binding at certain classes of sites does control early T-cell 
gene expression.  
 
Results 
Dynamic PU.1 occupancy at open and closed chromatin sites in pre-commitment pro-T 
cells 
In early, pre-commitment T-cell development (Fig. 1A), PU.1 occupancy starts at ~30,000 
genomic sites in DN1 and DN2a stages, globally distinct from the PU.1 sites in non-T lineage 
cells, then decreases to a subset of ~5000 scorable sites in newly-committed DN2b cells (Fig. 
1B), before PU.1 disappears at later stages (Zhang et al. 2012). To evaluate how PU.1 might 
select these sites, we examined whether chromatin status at the sites and the binding specificity 
of the protein itself could determine occupancy preferences. We used a sequence-agnostic 
criterion of regulatory site activity during the natural decrease of PU.1 during commitment (from 
DN1 and DN2a to DN2b and DN3). Activity states of chromatin were mapped at high resolution 
as changes in DNA accessibility (“openness”) using Analysis of Transposase-Accessible 
Chromatin (ATAC)-seq (Buenrostro et al. 2013). Fig. 1C shows examples of PU.1 occupancy 
patterns at the Cd34 and Bcl11a target genes, which are most highly expressed in pre-
commitment DN1 cells, correlated with ATAC status of the relevant sites before (DN1) and just 
after commitment (DN3). Although “permissive” H3K4me2 chromatin modifications change little 
across these stages in general (Zhang et al. 2012), these loci are linked with specific sites 
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where developmental loss of PU.1 binding during commitment is accompanied by losses of 
ATAC accessibility and H3K4me2 (Fig. 1C, highlighted regions). Considering all sites genome-
wide where PU.1 bound during any DN1-DN2b stage, ATAC criteria showed that more of these 
sites were likely to be “open” in DN1 stage (Fig. 1D, cyan) than in DN3 stage, when PU.1 levels 
were low (Fig. 1D, dark green). This suggests that PU.1 either causes these sites to open or is 
preferentially recruited to them because of their accessibility. 
 
Changes in ATAC status of PU.1 sites between DN1 and DN3 stage were strongly correlated 
with changes in expression of the closest linked gene. As shown by an empirical cumulative 
distribution frequency (ECDF) plot (Supplementary Fig. S1A), genes linked to PU.1 sites that 
lost accessibility during commitment (“closing sites”) were more likely to be downregulated 
(DN3/DN2a ratio <1, padj<0.1, blue arrow) than genes without PU.1 sites. Accordingly, genes 
linked to sites that increased accessibility (“opening sites”) were more likely to be upregulated 
(DN3/DN2a ratio >1, padj<0.1, red arrow). Taken together with the enrichment of open regions 
among all PU.1-occupied sites, this suggests that PU.1 could positively regulate hundreds of 
genes specific to precommitment cells.  However, PU.1 binding across the genome was not 
confined to open sites (Fig. 1D,E). In DN1 and DN2a cells, PU.1 occupied similar numbers of 
closed and open sites (Fig. 1E). Therefore, PU.1 does not simply engage sites epigenetically 
primed by other factors, nor does its binding always cause chromatin opening as scored by 
ATAC-seq.  
 
Distinct PU.1 affinity thresholds in open and closed chromatin and at promoter and non-
promoter sites 
In macrophages, PU.1 is a pioneer factor capable of displacing nucleosomes from its binding 
sites (Barozzi et al. 2014). In pro-T cells, where PU.1 expression is inherited from pre-thymic 
precursors but its best-characterized partner factors are absent, it was not clear whether PU.1 
 Cold Spring Harbor Laboratory Press on September 10, 2018 - Published by genome.cshlp.orgDownloaded from 
7 
 
led or followed other factors to select its sites. The definition of pioneering (Zaret and Carroll 
2011) implies that the DNA binding specificity of the factor itself guides its binding to sites in 
initially closed chromatin. We tested whether PU.1 intrinsic specificity guides its binding to 
“open” and “closed” sites by scoring PU.1 occupancy sites genome-wide for log-odds match to 
an optimal position weight matrix (PWM), calculated de novo (Supplementary Table S1, 
Supplementary Fig. S1B) from its pro-T cell binding sites (Zhang et al. 2012). The scoring 
pattern of sites across the genome (Fig. 1E,F) agreed well with the pattern scored using a more 
permissive PWM, calculated from PU.1 sites occupied in macrophages, which was reported to 
reflect PU.1 binding preferences on naked DNA (Pham et al. 2013)(Supplementary Fig. S1B,C). 
The canonical PU.1 motif was the most enriched, at all classes of sites (Supplementary Fig. 
S1D). However, at each stage, PU.1-occupied sites in open regions had a broader range of 
quality scores, with lower median and quartile quality scores, than the PU.1-bound sites in 
closed regions, implying that higher affinity was needed to establish binding at closed sites. The 
“closed” PU.1 binding sites accordingly showed a greater enrichment of a PU.1 subfamily 
(Sfpi1, SpiB) ETS motif than the “open” sites (Figs. 1G, S1D). On the other hand, open sites 
and the lower-quality half of the closed sites were distinguished from higher-quality closed sites 
by their high co-enrichment of RUNX family motifs (Figs. 1G, S1D).  
 
The changes in PU.1 occupancy across the genome as PU.1 levels naturally decrease in 
development implied that PU.1 binding site selection is governed by its own mass action. As 
PU.1 tag counts at individual sites and the number of scorable binding regions genome-wide 
both dropped during commitment (Fig. 1B), the sites still occupied were those with higher motif 
quality (Figs. 1F; S1C,E). However, distinct binding criteria applied in open and closed 
chromatin regions. Both open and closed regions lost PU.1 occupancy at DN2b stage (Fig. 1E, 
left), but the site quality difference between them persisted where PU.1 remained bound (Fig. 
1F, left; Supplementary Fig. S1E), consistent with a continuing affinity penalty in the closed 
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regions.  Matching site quality distributions at “closed” DN2a and “open” DN2b sites suggested 
that closure reduced PU.1 sensitivity by 4-5×. In the same cell nuclei, declining PU.1 levels also 
differentially affected binding at promoter and non-promoter (distal) sites. Promoter sites were 
occupied even when they had poor quality target motifs (Fig. 1F, right), and when PU.1 fell to 
lower levels, the promoter sites still occupied were poorer-quality than non-promoter sites. This 
global difference in binding criteria at promoter and non-promoter sites was seen at all stages, 
and even when open and closed promoter and non-promoter sites were compared separately 
(Supplementary Fig. S1E). Thus, PU.1 is recruited differently to promoters and enhancer 
elements. 
 
Non-promoter PU.1 sites control chromatin configuration and function 
Genome-wide PU.1 binding dynamics were correlated with changes in local chromatin status. 
Fig. 2A,B shows the ~40K sites of PU.1 occupancy in the pro-T genome, clustered based on 
PU.1 binding, ATAC accessibility, and H3K4me2 modification status from DN1 to DN2b or DN3 
stages. The majority of sites fell into either of two major groups (Fig. 2A, Group 1 and Group 2; 
k-means). One large group of sites comprised open sites that stayed highly accessible, 
independent of developmental stage or level of PU.1 binding (Fig. 2A,B, site Group 1, “static”). 
In contrast, about 60% of PU.1 occupancy sites in DN1 and DN2a cells lost accessibility, and 
sometimes even the “permissive” histone mark H3K4me2, as PU.1 expression declined in 
DN2b/DN3 stages (Fig. 2A,B; site Group 2, “closing”). A few sites also “opened” as PU.1 levels 
declined (see below), but did not cluster efficiently here. The static sites (Group 1) were highly 
enriched for annotated promoters (39.8% in promoter regions)(χ2 test p <0.0001), whereas the 
closing sites (Group 2) were overwhelmingly in non-promoter elements (only 4.6% peaks in 
promoter regions). Thus, the dominant division of PU.1 occupancies was into sites with 
constitutive accessibility and sites whose accessibility decreased in parallel with PU.1 
expression itself. 
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PU.1 binding at non-promoter sites, but not at promoters, was correlated with gene expression 
specifically before commitment. Genes linked only to Group 1 binding sites changed little in 
expression between DN2a (high PU.1) and DN3 (low PU.1) stages (Fig. 2C), even less (yellow 
arrow, p<0.0001) than genes without any PU.1 binding peaks at all (Fig. 2C, black curve). In 
contrast, genes linked to Group 2 PU.1 sites (Fig. 2C green) changed expression much more 
than genes without peaks, most of them losing expression in this developmental transition 
(green arrow, p<0.0001, skew to left), despite similar kinetics of retention of PU.1 between 
Group 1 and 2 sites (Supplementary Fig. S1F). These results suggest that PU.1 binding in pro-T 
cells is more stringent, more important for chromatin site accessibility, and better correlated with 
transcription when it binds at non-promoter regions than at promoters. 
 
To test whether PU.1 itself was responsible for the dynamics of ATAC accessibility at these 
non-promoter sites, we exploited the Cas9 transgenic mouse strain (Platt et al. 2014) to provide 
T-cell precursors in which PU.1 could be acutely deleted at a specific developmental stage (Fig. 
2D) (Hosokawa et al. 2018). Hematopoietic precursors from these mice were isolated and 
induced to begin T-lineage differentiation in vitro by coculture with OP9-DL1 stromal cells. When 
PU.1 was at its height during DN1 to DN2a stages, specific guide RNAs were introduced by 
retroviral transduction (sgSpi1 or sgControl), and effects on chromatin accessibility were 
assayed by ATAC-seq after four more days of culture. This deletes targeted exons biallelically 
(Supplementary Fig. S1G) and removes endogenous PU.1 expression (Hosokawa et al. 2018). 
While promoter sites were unaffected when PU.1 was deleted, many non-promoter sites 
specifically lost accessibility, far more than gained accessibility, and these affected sites were 
normally open in DN1 but not in DN3 stage (Fig. 2E). The sites with PU.1-dependent 
accessibility were indeed direct targets, for they were also significantly enriched among distal 
sites that normally bound PU.1 in control DN1 cells (Fig. 2F,G; p ≤ 0.0001). The whole 
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accessibility distribution of PU.1 binding sites in non-promoter regions shifted toward closure 
when Spi1 was disrupted (Fig. 2G, right). In contrast, PU.1 deletion had little if any effect on 
promoter sites, with or without PU.1 binding (Fig. 2E-G). Thus, sustained PU.1 activity is 
needed to maintain ATAC accessibility at many non-promoter PU.1 binding sites. 
 
PU.1 can bind its target sites independently of RUNX1 
The motifs most highly co-enriched with PU.1 motifs were for RUNX factors. In a related study, 
we have shown that PU.1 physically interacts with RUNX1 in pro-T cells and recruits it to PU.1 
binding sites (Hosokawa et al. 2018). Supplementary Fig. S2A shows that a large fraction of 
endogenous PU.1 occupancy sites that were open in primary DN1 cells were in fact co-
occupied by RUNX1 [data from (Hosokawa et al. 2018)], with highest RUNX1 binding 
enrichment among those sites with lower-quality PU.1 motifs (below median PWM score). 
RUNX1 co-occupancy was much lower at PU.1 sites in closed regions, consistent with motif 
enrichments (Fig. 1G, Supplementary Fig. S1D). These results raised the question of how much 
RUNX1 was contributing to the ability of PU.1 to establish occupancy at different classes of 
sites.  
 
Whereas primary cell recovery is severely inhibited by combined deletion of Runx1 and forced 
expression of PU.1, we could test the effect of RUNX1 loss on binding of exogenous PU.1 in the 
Scid.adh.2C2 model cell system. These are immortal, clonal DN3-like cells that do not express 
endogenous PU.1, but respond sensitively to introduction of exogenous PU.1 with responses 
similar to those of primary pro-T cells (Dionne et al. 2005; Del Real and Rothenberg 2013)(Fig 
3A). Scid.adh.2C2 cells were transduced with Cas9 followed by either control sgRNA (sgCtrl) or 
sgRNA against Runx1 (sgRunx1), and then transduced with exogenous PU.1 (Fig. 3B). This 
treatment biallelically disrupted the region around the first Met codon shared by all RUNX1 
isoforms (Supplementary Fig. S2B) and eliminated RUNX1 protein expression (Hosokawa et al. 
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2018). Fig. 3C shows how this affected PU.1 binding to non-promoter sites. The sites bound by 
exogenous PU.1 were more likely to be initially open in Scid.adh.2C2 cells if near sites where 
RUNX1 bound previously (Hosokawa et al. 2018)(tallied below plots in Fig. 3C). However, high-
quality PU.1 binding to these non-promoter sites was essentially unchanged by Runx1 
disruption, whether they had been previous sites of RUNX1 occupancy (Fig. 3C, right panel) or 
not (left panel). Thus, although RUNX1 can be important for PU.1 function in pro-T cells 
(Hosokawa et al. 2018), PU.1 does not depend on RUNX1 to establish its binding at open or 
closed sites. 
 
Pioneering by PU.1 in DN3-like cells: site choice and chromatin opening in a closed 
epigenetic landscape 
PU.1 not only maintained the open status of its normal binding sites but could also cause sites 
to open in closed chromatin, as shown using the Scid.adh.2C2 cell line to provide a defined, 
low-background pro-T-cell context. To place PU.1 activity under tight temporal control, 
Scid.adh.2C2 cells were transduced stably with a vector encoding full-length PU.1 linked to the 
ligand-binding domain of a tamoxifen-dependent estrogen receptor (PU1-ERT2)(Fig. 3A). Most 
of the PU.1 expressed in these cells is tethered in the cytoplasm, but the PU.1 can translocate 
quickly to the nucleus in response to 4-hydroxytamoxifen (4-OHT). This downregulates the pro-
T cell surface marker IL2RA (also known as CD25, used throughout this article) beginning by 
24h (Supplementary Fig. S2C), and upregulates the myeloid-cell surface marker Itgam (also 
known as CD11b) later (Dionne et al. 2005; Del Real and Rothenberg 2013). From 0 to 24h of 
stimulation with 0.1 μM 4-OHT, we compared the kinetics of PU.1 binding to the genome with 
changes in H3K27ac and ATAC accessibility at these sites (Fig. 3D,E; Supplementary Fig. 
S2D). Baselines were defined by control cells transduced with an “empty” control vector 
encoding ERT2 only (“EV”, “EV-ERT2”)(Fig. 3B,C)(gene expression effects: Supplementary 
Table S2). Two site groups were seen (Groups 3 & 4). There was some background signal at 
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0h: in Scid.adh.2C2 cells stably expressing PU1-ERT2, low levels of PU1-ERT2 reached the 
nucleus even without 4-OHT, unlike EV-ERT2 samples (Fig. 3D, Supplementary Fig. S2D,E). 
Sites occupied in the presence of these low levels of nuclear PU.1 were restricted to already-
active chromatin sites, based on ATAC accessibility and H3K27ac in non-transduced or EV-
transduced cells (Fig. 3D, Group 4; Supplementary Fig. S2D,E). However, 4-OHT treatment 
induced nearly 5× more PU.1 binding sites within 2h (Supplementary Fig. S2D,E), and most of 
this new binding was to Group 3 sites (Fig. 3D) that had no PU1-ERT2 binding at 0h and were 
closed in unperturbed Scid.adh.2C2 cells (Fig. 3E, Supplementary Fig. S2D,E). Examples are 
the highlighted sites in the Icam1 gene, which were also bound in DN1-DN2a cells by 
endogenous PU.1 (Fig. 3F). Like Group 1 sites of endogenous PU.1 in primary cells (Fig. 2A), 
51% of Group 4 sites were at promoters, contrasting with only 3.1% of Group 3 sites (χ2 p-value 
< 0.0001), and the PWM match quality for Group 3 sites was much higher than for Group 4 sites 
(Supplementary Fig. S2F). Binding to Group 3-type sites was confirmed with another exogenous 
PU.1 construct, PU1WTHA (see below), which preferentially occupied “closed” sites in these 
cells unlike “open” sites bound by endogenous ETS1 (Supplementary Fig. S2G). 
 
In this cell context, PU1-ERT2 exerted its main positive impact at closed, non-promoter Group 3 
sites, rapidly making them ATAC accessible. This response was maximal already within 2h 
(Figs. 3D,E; Supplementary Fig. S2D). Slightly later, ~50% of the Group 3 sites also acquired 
the active histone mark H3K27ac de novo, beginning at 2 h but with most signal observed by 8-
24h of PU.1 binding (Fig. 3D,E; Supplementary Fig. S2D). Genome-wide, genes responding to 
PU1-ERT2 binding at linked Group 3 sites also usually increased expression over the 24h 
period (Fig. 3G, green). In contrast, those linked only to binding at Group 4 sites showed even 
less increase than genes without closely linked PU.1 sites at all (Fig. 3G, yellow).  
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Many functionally important PU.1 sites were bound immediately: the sites occupied at 2h were 
as likely to predict expression of linked genes at 24h as sites that were occupied only at 8h or 
24h (Supplementary Fig. S3A). However, the kinetics of transcriptional response implied a 
stepwise process. The pattern of expression of DEGs closely linked to new PU1-ERT2 sites 
began to change from 2h onward (Supplementary Fig. S3B), but only about 1/3 of the genes 
that were eventually activated showed upregulation by 8h, despite maximal ATAC accessibility 
already; most were only activated by 24h (all p<10-9). Thus, PU.1 binding rapidly initiated local 
ATAC accessibility in previously closed chromatin sites enabling further steps resulting in local 
target gene activation, consistent with pioneering activity. 
 
Whereas binding of PU.1 to non-promoter sites most often exerted positive effects, if any, on 
linked genes, PU.1 introduction also repressed many genes in these cells (Dionne et al. 2005; 
Del Real and Rothenberg 2013).  Supplementary Fig. S3B shows that such repression could 
start early, often before most positive target genes were upregulated (2h vs. 8h; Supplementary 
Table S2). While much of this repression was likely indirect (Del Real and Rothenberg 2013; 
Champhekar et al. 2015; Hosokawa et al. 2018), some was accompanied by direct binding. For 
example, Il7r was substantially repressed as PU.1 bound to an open Group 4 site at its 
promoter (Supplementary Fig. S3C).  
 
Opening of closed chromatin by PU.1 mediates its developmental gene regulatory 
function 
Data in Figs. 1 and 2 have shown that PU.1 binding in steady state is correlated both with 
chromatin openness and with local gene expression, but correlation alone could not prove that 
PU.1 normally regulates these genes. Data in Fig. 3 show that PU.1 could induce chromatin 
opening and gene activation when introduced at high levels in a PU.1-negative cell-line context. 
To confirm whether PU.1 serves its normal function in pro-T cells through opening chromatin 
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around its non-promoter binding sites, acute perturbations of PU.1 had to be carried out in a 
primary-cell developmental context with dosage changes close to the normal range, and with 
changes in its local binding tested for direct linkage to genes showing changes in expression. 
The evidence is detailed in Supplementary Figs. S4, S5 and Tables S3-S7, and summarized in 
Fig. 4.  
 
Briefly, we determined the RNAs changing expression after acute gains of PU.1 function at the 
DN2b/DN3 stages, when endogenous activity was diminishing, and reciprocally, after losses of 
PU.1 function (as in Fig. 2D-F; & Fig. 4A). We introduced epitope-tagged exogenous PU.1 
(PU1WTHA), so that changes in transcription could be directly attributed to local binding of the 
exogenous PU.1 constructs. Supplementary Figs. S4A,B show the cellular features of this 
system. Exogenous PU1WTHA established occupancy at sites with the same site quality 
spectrum that the endogenous PU.1 had occupied earlier (Fig. 4B). Supplementary Fig. S4C-F 
show the patterns of gene expression change that resulted, and their relation both to normal 
pro-T development (Supplementary Tables S3, S4) and to likely physiological target genes 
affected by acute Spi1 deletion (Supplementary Tables S5, S6).  Supplementary Fig. S4E-G 
show the criteria used to focus on cells affected by PU.1 within the normal pro-T developmental 
trajectory (“PU1WTHA25”), minimizing second-order effects. The exogenous Spi1 in these 
experiments was expressed at about 3-4× its endogenous DN1-cell level (Supplementary Table 
S3). Exogenous PU.1 in these cells altered gene expression in rough agreement with normal 
developmental trends of the affected genes (Supplementary Fig. S4H), and especially well in a 
curated “developmental index” gene set (Supplementary Fig. S4I; Supplementary Table S4). 
Most genes affected in PU1WTHA25 cells were upregulated, especially those with direct PU.1 
binding (Supplementary Fig. S4J).  
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PU1WTHA established occupancy at most sites that endogenous PU.1 had occupied before 
(Fig. 4C, “Exo PU.1” vs. “PU.1”), at both non-promoter (Group 5) and promoter-enriched (Group 
7) sites, as well as a group of sites that were normally not occupied by endogenous PU.1 
(Group 6). The Group 5 and Group 7 sites respectively resembled Group 2 and Group 1 sites of 
endogenous PU.1 binding in chromatin dynamics and site qualities (Fig. 4C; Supplementary Fig. 
S5A,B). Group 6 sites had high-quality motifs but were normally closed and not bound by 
endogenous PU.1 (Supplementary Fig. S5A,B)(Supplementary Table S7). However, the genes 
upregulated in PU1WTHA25 cells were enriched not only for Group 5 sites but also for Group 6 
sites (Fig. 4D; Supplementary Fig. S5C), i.e., where default chromatin states without 
PU.1WTHA would have been closing or closed. PU1WTHA binding to promoter-enriched Group 
7 sites again resulted in minimal change.  
 
Globally, the dynamic status of site accessibility in normal development predicted the direction 
of response of a linked gene (Supplementary Fig. S5D-F): PU1WTHA tended to activate genes 
linked to sites that normally closed as endogenous PU.1 declines (“closing sites”, Kolmogorov-
Smirnov p<2.2×10-16; Fig. 4E, blue arrow), while it had little or negative effect on genes linked to 
sites that would normally open as endogenous PU.1 declines (“regions opening”; Fig. 4E, red 
arrow). Thus, acute transcriptional changes caused by PU.1 in pro-T cells were tightly linked 
with its engagement at non-promoter sites where chromatin accessibility normally follows PU.1 
expression. This supports a normal mechanism of PU.1 action via chromatin accessibility.  
 
PU.1 requires its non-DNA binding domains to occupy sites in closed chromatin 
To assess the domains needed for pioneering activity within the PU.1 protein, we mapped the 
genomic sites occupied by the isolated PU.1 DNA binding domain alone (PU1ETSHA) as 
compared to full-length PU.1 (PU1WTHA). To relate this binding to function comparable to 
PU1WTHA, we also tested a dominant negative PU1ETSHA derivative, PU1ENGHA (constructs 
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diagrammed in Supplementary Fig. S6A), which primarily repressed targets rather than 
activating them (Supplementary Fig. S6B). Both truncated forms bound to DNA with site quality 
criteria similar to those of PU1WTHA (Supplementary Fig. S6C), and in primary pro-T cells, 
PU1ENGHA exerted its effects preferentially on sites that would normally close from DN1 to 
DN3 (Supplementary Fig. S6D), like sites preferred for function by PU1WTHA (cf. Fig. 4E). 
However, when PU1WTHA, PU1ETSHA, and PU1ENGHA were introduced into Scid.adh.2C2 
cells, both truncated constructs bound quite differently from full length PU.1 (Supplementary Fig. 
S6E, F), with much greater biases to promoter sites and reduced binding at non-promoter sites. 
Thus, whereas PU1WTHA bound both to normal sites of PU.1 occupancy in pro-T cells and 
some additional ones, the truncated constructs in these cells bound well only to a subset of 
natural PU.1 sites (Supplementary Fig. S6G, Group B). 
 
The sites that were poorly bound by PU1ETSHA and PU1ENGHA in Scid.adh.2C2 cells were 
not poor-quality in sequence, for in primary pro-T cells these sites (Supplementary Fig. S6G,H, 
Group A sites) could be bound by PU1ENGHA as well as the sites that were accessible in the 
Scid.adh.2C2 cells (Group B sites). In primary cells, also, the Group A sites were even better at 
mediating the repressive effect of PU1ENGHA (Supplementary Fig. S6I) than the Group B sites, 
which were constitutively open and promoter-enriched. The difference, however, was that Group 
A sites were in much less accessible chromatin in Scid.adh.2C2 cells (Supplementary Fig. 
S6G). Fig. 5A-D show Cd34, Robo1, Syk, and Ffar2, all positively regulated by full-length PU.1 
and repressed by PU1ENGHA in primary cells (Supplementary Table S3), which exemplify this 
context-dependent differential binding (highlighted) at Group A-type sites. Supplementary Fig. 
S7 shows additional examples: Cd44, Vav1, Elovl5, Flt3, Notch2, and Myd88.  
 
The failure of the isolated PU.1 DNA binding domain (or its derivative) to interact with these 
sites in the context of the DN3-like cell line suggested that PU.1 without its native trans-
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activation and protein-interaction domains could be more sensitive to chromatin state for access 
to its binding sites than full-length PU.1. We tested whether the truncated constructs really have 
a qualitative requirement for open chromatin, or whether they simply have lower affinity or reach 
lower effective protein concentrations. First, we compared binding success of PU1WTHA and 
PU1ENGHA in primary CD25+ cells at sites of different PWM quality scores with open vs. closed 
ATAC status. Here, PU1ENGHA bound comparably to PU1WTHA at open sites (Fig. 5E). 
However, whereas PU1WTHA showed the expected affinity cost for entry into closed chromatin, 
PU1ENGHA showed much less binding at closed sites, even those with very high-quality motifs 
(Fig. 5E). Wildtype and truncated constructs also showed sharply different binding to target sites 
in SCID.adh.2C2 cells depending on whether they were ATAC-open or ATAC-closed.  Fig. 5F 
shows the occupancies of the same open and closed sites by PU1WTHA, PU1ENGHA, or 
PU1ETSHA, all compared to PU1WTHA (detected by a different antibody). In these graphs, 
identical binding falls on the diagonal, as seen when the same PU1WTHA was detected with 
αPU.1 or with αHA antibodies. Global DNA-binding efficiency differences between a truncated 
construct and the full-length form should shift the whole trend line downward on the log/log plot 
or change its slope. Instead, Fig. 5F shows that the truncated constructs gave a split pattern. 
Both truncated constructs closely matched PU1WTHA on open sites (red), but were specifically 
penalized, within the same cells, with lower binding slopes and high dispersions at closed sites 
(blue). Thus, the non-DNA binding domains of PU.1 strongly and selectively affected the ability 
of the PU.1 DNA binding domain to establish occupancy in closed chromatin. 
 
DISCUSSION  
PU.1 is known to act as a pioneer in the role of a lineage determining factor that initiates and 
sustains identity of myeloid cells (Natoli et al. 2011; Barozzi et al. 2014). In this study we have 
asked whether its inherited high activity in the earliest pro-T cells also shapes the epigenetic 
landscape in this context, even though its activity in this lineage is hit and run and many of its 
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known partners are not expressed. Criteria for pioneering involve the ability to open closed 
chromatin and to initiate occupancy of a cis-regulatory site by a complex of transcription factors 
(Zaret and Carroll 2011). Logically, this implies that pioneer factors can (1) find and bind to sites 
in closed chromatin; (2) bind to target sequences based on their own specificity, even before 
other factors are available to collaborate; and (3) initiate the opening of chromatin as new 
partners are recruited. In the myeloid system, PU.1 often plays these roles as part of a 
partnership with C/EBP family factors, where either PU.1 or the C/EBP factor can help nucleate 
binding by the other (Laiosa et al. 2006; Feng et al. 2008; Heinz et al. 2010; Heinz et al. 2013). 
As we show here, PU.1 also fulfills most of the criteria for pioneering in pro-T cells. It can bind 
closed chromatin as well as open. Its binding is primarily guided by its own well-defined 
specificity, although its binding to closed chromatin sites in these cells requires a consistently 
higher affinity of site recognition than binding to open chromatin. Its binding preferences as its 
concentrations drop during T-cell development are consistent with mass-action in which the 
dissociation constant is dominated simply by PU.1’s own specificity. Finally, it can trigger 
chromatin opening, and is required continuously to maintain accessibility at many of its target 
sites. These functions are exerted especially at a major subset of its non-promoter sites, where 
PU.1 can rapidly induce transposase accessibility followed by recruitment of histone 
acetyltransferases. It may cooperate with RUNX1 in causing chromatin to open and to activate 
its positive target genes (Hosokawa et al. 2018), but does not require RUNX1 for its own 
binding. This is summarized in Fig. 6.  
 
ChIP-seq analysis, short-term forced expression and acute, synchronized CAS9-mediated 
deletion tests have robustly defined the positive regulatory targets of direct PU.1 binding in early 
pro-T cells. A core group of about 250 genes is positively regulated by PU.1 based on gain and 
loss of function in pro-T cells (Supplementary Table S6), and these genes are linked to non-
promoter sites of PU.1 binding that depend on PU.1 for ATAC accessibility and lose 
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accessibility when PU.1 levels decline. We have also identified a minority of negative regulation 
targets that are also likely to be direct. These high-confidence target genes of PU.1, both 
positive and negative, show direct binding, chromatin features at PU.1 sites and developmental 
expression all implying that normal endogenous PU.1 activity is a major controller of their site 
accessibilities during normal pro-T cell development.  
 
The high developmental resolution possible in this system sheds light on features of PU.1 action 
that have much broader implications. The first is that motif quality of sites, magnitudes of 
occupancy, promoter-association, and immediate degrees of ATAC accessibility are useful but 
not sufficient criteria to identify loci of actual PU.1 regulatory action. Promoters are by far the 
most accessible sites for PU.1 binding: not only are they constitutively open as measured by 
ATAC-seq, but also they offer an exceptionally permissive affinity threshold for PU.1 
engagement, and they do not require the PU.1 transactivation domains for efficient PU.1 
binding. In myeloid cells, PU.1 is commonly bound at promoter-proximal regulatory elements of 
functional target genes (Gonzalez et al. 2015). However, although PU.1 is frequently bound to 
promoters of active genes in pro-T cells as well, in this cell context the actual functional impact 
of its activity at these promoters is often weak or null, unless supplemented by local binding to 
non-promoter sites as well. Instead, it is those dynamic distal elements, even those with less-
pronounced PU.1 binding, that are best associated with function. 
 
PU.1 binding is excluded by H3K27me3-marked repressive chromatin (Zhang et al. 2012), but 
modestly elevated PU.1 can also enter other regions that appear “inaccessible” by criteria of 
ATAC-seq, and upon binding can mediate rapid chromatin opening and local gene activation. 
However, we have shown that the ability to establish binding in such closed sites depends on a 
function of PU.1 structurally distinct from its site recognition. As in the case of EBF1 (Boller et al. 
2016), although the PU.1 DNA-binding domains define its nucleotide sequence specificity, the 
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non-DNA binding domains of PU.1 are required for its access to closed sites. Thus, the DNA 
binding domain alone is not only deprived of discrete transactivation or protein interaction 
functions, but also of access to a large subset of potential genomic targets. This effect explains 
some of the functional specificity of the obligate-repressor PU1ENGHA form as previously 
reported (Champhekar et al. 2015), which can compete with endogenous PU.1 at open binding 
sites but cannot gain access to those sites once they have developmentally closed. The non-
DNA binding domains of PU.1 are important for its interactions with protein partners, at least 
including RUNX1 and SATB1 in early pro-T cells (Hosokawa et al. 2018), IRFs (Escalante et al. 
2002), and factors important in erythroid development (Zhang et al. 2000; Stopka et al. 2005). 
Although RUNX1 itself may not explain this specific binding requirement, other interacting 
proteins (Hosokawa et al. 2018) remain as candidates to assist PU.1 binding in closed 
chromatin of pro-T cells. Thus, the full site-selectivity of PU.1 as a pioneer depends not only on 
its ability to find high-affinity sites, but also on the ability of its protein-interaction domains to 
convert recognition of sites in closed chromatin into stable, functional occupancy. 
 
Thus, despite PU.1’s fulfillment of simple criteria of pioneer function, its impact on early T-
lineage cells is determined by the intersection of its own powerful binding activity and its 
dynamic interaction with other determinants of epigenetic state. The effect of closed chromatin 
on full-length PU.1 appears to be quantitatively compensated by the higher binding affinities at 
nearer-optimal sites, but the transcriptional effect of this PU.1 binding on neighboring genes 
depends on other factors that influence whether the site bound is constitutively open, 
constitutively closed, or may be dynamically opening or closing in development. This reconciles 
the biochemical pioneering-like activities of PU.1 with its distinctive lineage-specific occupancy 
patterns and functional impacts in the earliest stages of T-cell development. 
 
METHODS 
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Full methods and a full reagent list are provided in Supplemental Material. Briefly: 
Mice and cells. As a source of primary cells, C57BL/6 mice and mice with Cas9 and Bcl2 
transgenes on a C57BL/6 background were used as described previously (Hosokawa et al. 
2018). Fetal liver precursors (Zhang et al. 2012; Del Real and Rothenberg 2013; Champhekar 
et al. 2015), and bone marrow precursors for the CAS9-mediated deletion experiments 
(Hosokawa et al. 2018) were prepared as described. All mouse husbandry and procedures were 
reviewed and approved by the Caltech Institutional Animal Care and Use Committee. 
Scid.adh.2C2 cells (Dionne et al. 2005; Del Real and Rothenberg 2013) were cultured as in 
(Hosokawa et al. 2018). In vitro T-lineage development using OP9-DL1 cocultures and analysis 
by flow cytometry were described previously (Champhekar et al. 2015; Hosokawa et al. 2018). 
Details of flow cytometric staining, marker terminology, antibodies, and culture conditions in 
each experiment are detailed in Supplemental Material. 
Retroviral constructs. Exogenous PU.1 constructs in LZRS retroviral vectors and PU.1 in a 
pMXs derivative were previously described (Champhekar et al. 2015; Hosokawa et al. 2018). 
Cas9 was cloned into a pMSCV derivative and guide RNAs into an mTurquoise derivative of 
pQCXIN described in Supplemental Material.   
ChIP-seq, ATAC-seq and RNA-seq. Standard RNA-seq and ChIP-seq methods were used as 
in our related report (Hosokawa et al. 2018), and ATAC-seq followed standard procedures 
(Buenrostro et al. 2013). Data for these studies have been deposited as reported previously 
(GSE93755, GSE11020). Details of sample processing, antibodies, sequence processing and 
data analysis are presented in full in Supplemental Material. Analyses of binding patterns and 
differential gene expression used HOMER (Heinz et al. 2010) and other publicly available 
packages. Alignments shown are to mm9 (NCBI37) for comparability with previous results 
(Zhang et al. 2012). All sample types were generated in 2-4 separate biological replicates, with 
inter-sample correlations as shown in Supplementary Figs. S4 and S8. Detailed methods of 
statistics and bioinformatics are presented in Supplemental Material.  
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FIGURE LEGENDS 
 
Figure 1: Endogenous PU.1 binding in pro-T cells: distinct affinity thresholds for binding 
at open and closed sites and promoter and non-promoter sites.  
A) Outline of early T-cell development with schematic depicting PU.1 expression levels. B) 
Number of endogenous PU.1-occupancy peaks detected in DN1, DN2a, and DN2b pro-T cells. 
C) Cd34 and Bcl11a UCSC Genome Browser tracks (http://genome.ucsc.edu) showing 
endogenous PU.1 ChIP, ATAC-seq, H3K4me2 ChIP, and RNA-seq in the DN1, DN2a, DN2b, 
and/or DN3 stages. Samples from in vitro differentiation from fetal liver precursors or from 
thymus (DN1, DN3). Data from GSE31235; GSE93755. D) Histogram of ATAC tag-counts at 
DN1 (top) or DN3 (bottom) stages, across all pro-T cell PU.1 binding sites. Sites in regions 
defined as ATAC ‘open’ or ‘closed’ (see Methods) are plotted separately to aid visualization. Y 
axis: number of sites at indicated ATAC signal level. E) Number of PU.1 peaks in indicated 
stages in ATAC-open and ATAC-closed as well as promoter and non-promoter regions. Same 
color key is used in (E) and (F).  F) Distribution of DN1-DN2b motif log-odds scores at binding 
sites in open (cyan; open in DN1, green open in DN3) and closed regions (magenta closed in 
DN1, black; closed in DN3), and in promoters (dark blue) and non-promoter (orange) elements. 
Scores from a DN1-DN2b derived PU.1 PWM-matrix (Supplementary Table S1). Kruskal-Wallis 
statistical test, *** p ≤ 0.0001. G) Motif analyses of PU.1 sites in DN1-DN2a cells, classified by 
PWM scoring and ATAC accessibility in DN1.  
 
Figure 2: PU.1 loss reduces chromatin accessibility at non-promoter sites.  
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A) Heatmap of PU.1 and ATAC tag count distribution in early DN-pro-T development. Two kb-
wide regions were k-means clustered (k=2) based on PU.1 binding, ATAC, and H3K4me2 
patterns. Group 1: constitutively open sites. Group 2: sites losing accessibility from DN1 to DN3. 
B) ATAC and H3K4me2 distributions at the indicated stages at sites in Groups 1 and 2. Arrows 
in H3K4me2 plot: nucleosome re-constitution after PU.1 loss. C) Natural changes in gene 
expression across commitment (DN2a to DN3) linked to Group 1 (static) and 2 (closing) sites. 
*** Kolmogorov-Smirnov p-value ≤ 0.0001. D) Schematic of protocol for CAS9-mediated 
disruption of PU.1 using transduction with sgSpi1 or control guide RNAs. E) Effects of disruption 
of PU.1 in DN2 cells on accessibility of promoter and non-promoter sites. X axis: ATAC 
accessibility of individual sites in DN1 stage; y axis, accessibility in DN3 stage. Blue: sites that 
lose accessibility upon PU.1 deletion in DN2 cells; red: (rare) sites that gain accessibility. F) 
Enrichment of PU.1-binding sites among genomic sites that lose ATAC accessibility upon PU.1 
deletion. ATAC-accessibility of genomic sites after PU.1 deletion (y axis) is plotted against their 
accessibility in controls (x axis). Red: sites overlapping with PU.1 binding in DN1, DN2a, and/or 
DN2b cells. G) Effects of PU.1 knockout on accessibility of promoter and non-promoter PU.1 
binding sites.  *** Kolmogorov-Smirnov p-value ≤ 0.0001. 
 
Figure 3: Induction of PU.1 activity leads to chromatin opening, altered histone 
modifications and cis-regulatory element-dependent gene activation  
A) Schematic of experiment showing approximate relationship of Scid.adh.2C2 cells to normal 
program of T-cell development. B) Schematic of test in Scid.adh.2C2 cells to determine whether 
exogenous PU.1 site binding is RUNX1-dependent. C) Results of protocol shown in B. PU.1 
occupancy scores for PU.1 binding in cells after Runx1 disruption (y axis) are plotted against 
scores for PU.1 binding in controls (detected with αPU.1). Sites are stratified according to their 
ATAC accessibility and RUNX1 occupancy in unmanipulated Scid.adh.2C2 cells (Hosokawa et 
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al. 2018). Pearson’s r and linear trend lines are shown for peaks with a peak score (Homer 
findPeaks) >30 in controls. D) Time courses of PU.1 binding, induced changes in chromatin 
accessibility, and histone H3K27 acetylation after 0-24h of mobilization by 4-hydroxytamoxifen 
(4-OHT), in Scid.adh.2C2 stably transduced to express PU1-ERT2 or EV-ERT2. Sites in heat 
map were hierarchically clustered on Pearson correlation with average linkage. Shown are 
manually derived groups of sites that open and gain H3K27ac upon PU1-ERT2 mobilization 
(Group 3) or that are already open and associated with H3K27ac at 0h (Group 4). E) 
Quantitative distribution plots of PU.1, ATAC and H3K27ac signals within 1 kb of Groups 3 and 
4 PU.1 bound sites. F) PU.1 binding to the positively regulated Icam1 gene in DN1-DN2b cells 
(top) and samples from the time course shown in Fig. 3D. Highlight indicates chromatin regions 
opened by PU.1 binding prior to RNA expression. G) Association of PU1-ERT2 binding site 
Groups 3 & 4 with changes in linked gene expression between 0h and 24h of 4-OHT induction. 
*** Kolmogorov-Smirnov p-value ≤ 0.0001.   
 
Figure 4. Causality test: sites bound by exogenous PU.1 that mediate function in pro-T 
cells 
A) Schematic of experiments shown in this figure and Figs. S4, S5: acute gain and loss of 
function of PU.1 in developing primary pro-T cells. CD25+ cells (DN2 to DN3) are cells within the 
T-cell pathway. B) Comparison of site occupancies by endogenous PU.1 (DN1-DN2b, detected 
by αPU.1) and by exogenous PU.1 (PU1WTHA, detected by αHA) as a function of PWM score, 
at “open” and “closed” sites. C) Heatmap of binding of exogenous PU1WTHA in CD25+ 
DN2b/DN3 primary cells (Exo PU.1), compared with endogenous PU.1 in DN1, DN2a, and 
DN2b, ATAC-seq in DN1 and DN3, and H3K4me2 and H3K27me3 in DN1 and DN3 cells. Color 
scales: tag count densities. D) Association of Groups 5, 6, and 7 sites with changes in linked 
gene expression induced by exogenous PU1WTHA in CD25+ cells. *** K-S p-value ≤ 0.0001, ** 
p-value ≤ 0.001,* p-value ≤ 0.05. E) Changes in gene expression induced by acute PU1WTHA 
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introduction in genes linked to sites that would normally close (blue) or open (red) from DN1 to 
DN3, as compared to genes with no PU1WTHA peaks or genes with a mixture of opening and 
closing peaks. Left: genes with significant differential expression induced in cells remaining 
CD25+.  
 
Figure 5: Full-length PU.1 is required for access to closed chromatin 
A)-D) UCSC Genome Browser tracks comparing binding of endogenous PU.1, full-length 
exogenous PU1WTHA, and PU1ENGHA to open and closed regions in primary DN2b/3 CD25+ 
cells and Scid.adh.2C2 cells. Shown are the genes: A) Cd34, B) Robo1, C) Syk, D Ffar2.  E) 
Comparison of PU1ENGHA binding with that of PU1WTHA and baseline binding of endogenous 
PU.1 in primary DN2b cells. Analysis as in Fig. 4B. Green bars: open sites in primary DN2b-
DN3 cells. Gray bars: closed sites. Dashed line: background.  F) Comparison of exogenous 
PU1WTHA with PU1ENGHA or PU1ETSHA binding in transduced Scid.adh.2C2 cells at open 
and closed promoter and non-promoter sites. PU1WTHA αHA counts in open (red) and closed 
(blue) regions are plotted against PU1WTHA αPU.1 (left), PU1ENGHA αHA (middle) or 
PU1ETSHA αHA (right) tag counts in promoters (top three panels) or non-promoter genomic 
sites (bottom three panels). n, peaks at open promoters=4498; n, peaks at closed 
promoters=810; n, peaks at open non-promoter elements=8719; n peaks at closed non-
promoter elements=33158. Pearson’s r shown. Dashed lines: tag threshold for peaks 
considered bound. 
 
Figure 6: Schematic of PU.1 site choice criteria and functional impacts in pro-T cells. 
Summary of mechanisms regulating PU.1 binding and function (see Discussion). 
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